Open an Account
search icon
1
NOTIFICATIONS
Best Algo trading app in India
Bigul

Glenmark Life Sciences Ltd - 543322 - Closure of Trading Window

 We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Wednesday, November 10, 2021, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2021. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from September 30, 2021 to November 12, 2021 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2021. The above is for your information.
01-11-2021
Bigul

Glenmark Life Sciences Ltd - 543322 - Board Meeting Intimation for Unaudited Financial Results Of The Company For The Second Quarter And Half Year Ended September 30, 2021

 Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2021 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2021
01-11-2021
Bigul

Glenmark Life Sciences Ltd - 543322 - Statement Of Investor Complaints For The Quarter Ended September 2021

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0100964 Name of the Signatory :- Rudalf CorrieaDesignation :- Company Secretary and Compliance Officer
21-10-2021
Bigul

Glenmark Life Sciences Ltd - 543322 - Shareholding for the Period Ended September 30, 2021

 Glenmark Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here
20-10-2021
Bigul

Glenmark Life Sciences Ltd - 543322 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

 Glenmark Life Sciences Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here
08-10-2021
Bigul

Glenmark Life Sciences Ltd - 543322 - Submission Of Scrutinizer'S Report And Voting Result Of Postal Ballot

 In furtherance of our intimation dated September 7, 2021 regarding notice of Postal Ballot and in terms of applicable provisions of SEBI (Listing obligations and Disclosure Requirements) Regulations 2013, as amended, we would like to inform you that the Special Business relating to Material Related Party Transactions with Glenmark Pharmaceuticals Limited as set out in the postal ballot notice have been passed with requisite majority. In this regard please find enclosed a) E-Voting results under Regulation 44(3) of the SEBI (Listing Regulations) 2015 b) Scrutinizer's Report This is for your Information and records.
07-10-2021
Bigul

Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the copy of the newspaper advertisement informing about Postal Ballot Notice/E-voting published in Financial Express and Loksatta. The same has been made available on the Company's website www.glenmarklifesciences.com You are requested to kindly take the above information on record.
08-09-2021
Bigul

Glenmark Life Sciences Ltd - 543322 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

 Postal Ballot Notice - Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
07-09-2021

Glenmark Life Sciences Q1 profit rises to Rs 100.9 cr; revenue up 32.2%

 Revenues from generic API segment increased 38.3% YoY to Rs 4,803 crore during Q1, driven by growth across all geographies
13-08-2021
Bigul

Glenmark Life Sciences Ltd - 543322 - Unaudited Financial Results For The First Quarter Ended June 30, 2021

 Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the First Quarter ended June 30, 2021. The said meeting of the Board commenced at 10.00 a.m. and concluded at 12.10 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarklifesciences.com You are requested to take the same on record.
13-08-2021
Next Page
Close

Let's Open Free Demat Account